BLA 103792 · Genentech
Herceptin
Trastuzumab · Intravenous · HER2/neu Receptor Antagonist
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Sep 25, 1998
Approved uses
10
Original approval plus efficacy supplements
Registered trials
1,500
287 Phase 3, 274 recruiting
FAERS reports
68,519
58,724 serious, 8,254 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning Cardiomyopathy: Herceptin can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Herceptin for cardiomyopathy. ( 2.5 , 5.1 ) Infusion Reactions, Pulmonary Toxicity: Discontinue Herceptin for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. ( 5.2 , 5.4 ) Embryo-Fetal Toxicity: Exposure to Herceptin during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Advise patients of...
What it is approved for
From the label in effect May 29, 2026.
Herceptin is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin ( 1 , 2.2 ). 1.1 Adjuvant Breast Cancer Herceptin is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi-modality anthracycline based therapy. Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin [see Dosage and Administration (2.2) ] . 1.2 Metastatic Breast Cancer Herceptin is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. Select patients for therapy based on an FDA-authorized companion diagnostic for Herceptin [see Dosage and Administration (2.2) ] . 1.3 Metastatic Gastric Cancer Herceptin is indicated in adults, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA-authorized companion diagnostic for...
Mechanism: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro , Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 18, 2024 Supplement 5354 · Efficacy LetterLabel
- Mar 7, 2014 Supplement 5311 · Efficacy · priority review LabelOtherLetter
- Oct 20, 2010 Supplement 5250 · Efficacy · priority review OrphanLabelLetter
- May 22, 2008 Supplement 5189 · Efficacy ReviewLetterLetter
- May 22, 2008 Supplement 5187 · Efficacy ReviewLetterLetter
- Jan 18, 2008 Supplement 5175 · Efficacy LabelReviewLetter
- Nov 16, 2006 Supplement 5150 · Efficacy · priority review LabelLetter
- Aug 28, 2002 Supplement 5008 · Efficacy LabelLetter
- Dec 11, 2001 Supplement 5004 · Efficacy LabelLetter
- Sep 25, 1998 Original approval · Type 1 - New Molecular Entity · priority review LabelReviewLetter
1 products under this application
- HERCEPTIN · TRASTUZUMAB 21MG/ML · VIAL, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trastuzumab" as an intervention, any sponsor and status, largest first.
- ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00490139 · 8,381 participants · Start May 16, 2007 · Primary completion Dec 6, 2013
Drug: Lapatinib; Trastuzumab · For: Neoplasms, Breast
Sites: Mobile, Alabama; Anchorage, Alaska; Tucson, Arizona · 924 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00045032 · 5,099 participants · Start Nov 2001 · Primary completion Mar 2005
Drug: Herceptin; Herceptin · For: Breast Cancer
Sites: Buenos Aires, Argentina; Geelong, Australia; Toowoomba, Australia · 203 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01358877 · 4,804 participants · Start Nov 8, 2011 · Primary completion Dec 19, 2016
Drug: 5-Fluorouracil; Carboplatin and 8 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Everett, California; Greenbrae, California · 546 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- Trastuzumab in Treating Women With HER2-Positive Early Breast CancerPivotal-lookingStatus unknown
Warwick Medical SchoolAcademic, hospital or other
NCT00712140 · 4,000 participants (planned) · Start Oct 2007 · Primary completion Oct 2011
Drug: trastuzumab; parenteral chemotherapy · For: Breast Cancer
Sites: Cambridge, United Kingdom; Carlisle, United Kingdom; Derby, United Kingdom · 11 sites in all
- BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabPivotal-lookingTerminated
NSABP Foundation IncResearch network
NCT00625898 · 3,509 participants · Start Apr 2008 · Primary completion Jun 2013
Drug: Docetaxel; Trastuzumab and 5 more · For: Breast Cancer
Sites: Birmingham, Alabama; Decatur, Alabama; Huntsville, Alabama · 649 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea6,727
- alopecia5,032
- nausea4,582
- fatigue4,414
- off label use4,273
- death3,634
- disease progression3,611
- myelosuppression3,242
- vomiting3,054
- dyspnoea2,795
- pyrexia2,541
- asthenia2,348
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 372 |
| 2005 | 377 |
| 2006 | 529 |
| 2007 | 587 |
| 2008 | 654 |
| 2009 | 973 |
| 2010 | 1,225 |
| 2011 | 1,190 |
| 2012 | 2,644 |
| 2013 | 2,889 |
| 2014 | 2,389 |
| 2015 | 2,682 |
| 2016 | 2,839 |
| 2017 | 4,453 |
| 2018 | 5,684 |
| 2019 | 4,963 |
| 2020 | 5,107 |
| 2021 | 4,903 |
| 2022 | 4,743 |
| 2023 | 5,016 |
| 2024 | 6,903 |
| 2025 | 4,330 |
| 2026 | 3,067 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Herceptin (Trastuzumab)
2024 spending
$4.7M
Beneficiaries
122
919 claims
Per beneficiary
$38,467
$1,505.59 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,712,224 |
| 2021 | $8,175,872 |
| 2022 | $5,953,812 |
| 2023 | $4,383,515 |
| 2024 | $4,692,925 |
Part B: Herceptin (Trastuzumab) · HCPCS J9355
2024 spending
$92.6M
Beneficiaries
2,840
24,605 claims
Per beneficiary
$32,612
2024 ASP limit $79.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $461,739,445 |
| 2021 | $223,709,771 |
| 2022 | $155,340,135 |
| 2023 | $108,679,973 |
| 2024 | $92,619,460 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Tolaney SM, Jiang Z, Zhang Q, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.
Shitara K, Van Cutsem E, Gümüş M, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.